p53 and its mutants in tumor cell migration and invasion
暂无分享,去创建一个
[1] Julie A. Wilkins,et al. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma , 2010, The Journal of pathology.
[2] Christopher W. Wong,et al. RCP is a human breast cancer-promoting gene with Ras-activating function. , 2009, The Journal of clinical investigation.
[3] Lakshmanane Boominathan. The Tumor Suppressors p53, p63, and p73 Are Regulators of MicroRNA Processing Complex , 2010, PloS one.
[4] Ker-Chau Li,et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug , 2009, Nature Cell Biology.
[5] H. Izumi,et al. Twist and p53 reciprocally regulate target genes via direct interaction , 2008, Oncogene.
[6] M. Oren,et al. Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities* , 2002, The Journal of Biological Chemistry.
[7] E. Sahai,et al. Imaging amoeboid cancer cell motility in vivo , 2008, Journal of microscopy.
[8] Anne J. Ridley,et al. Mammalian Rho GTPases: new insights into their functions from in vivo studies , 2008, Nature Reviews Molecular Cell Biology.
[9] S. Jakowlew. Transforming growth factor-β in cancer and metastasis , 2006, Cancer and Metastasis Reviews.
[10] H. Kotani,et al. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. , 2006, Cancer research.
[11] C. Prives,et al. p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.
[12] Victoria Sanz-Moreno,et al. Rho-GTPase signaling drives melanoma cell plasticity , 2009, Cell cycle.
[13] Christopher E Barbieri,et al. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. , 2006, Cancer research.
[14] Keara M. Lane,et al. Dicer1 functions as a haploinsufficient tumor suppressor. , 2009, Genes & development.
[15] S. Hsue,et al. Expression of p63 (TA and deltaN isoforms) in human primary well differentiated buccal carcinomas. , 2004, International journal of oral and maxillofacial surgery.
[16] M. Fraga,et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors , 2003, Journal of Cell Science.
[17] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[18] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[19] A. Ridley,et al. Inhibition of ROCK by RhoE. , 2006, Methods in enzymology.
[20] T. Jacks,et al. The role of p53 in tumour suppression: lessons from mouse models , 1999, Cellular and Molecular Life Sciences CMLS.
[21] S. Nomoto,et al. ΔNp63α and TAp63α regulate transcription of genes with distinct biological functions in cancer and development , 2003 .
[22] G. Hannon,et al. The miRNA-Processing Enzyme Dicer Is Essential for the Morphogenesis and Maintenance of Hair Follicles , 2006, Current Biology.
[23] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[24] Hartmut Land,et al. Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility , 2007, Nature Structural &Molecular Biology.
[25] R. Knight,et al. TAp63 and ΔNp63 in Cancer and Epidermal Development , 2007 .
[26] G. Bossi,et al. Mutant p53-induced Up-regulation of Mitogen-activated Protein Kinase Kinase 3 Contributes to Gain of Function* , 2010, The Journal of Biological Chemistry.
[27] V. Rotter,et al. Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.
[28] R. Knight,et al. TAp63 and DeltaNp63 in cancer and epidermal development. , 2007, Cell cycle.
[29] O. Renner,et al. Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models , 2010, PloS one.
[30] T. Mak,et al. Regulation of PTEN transcription by p53. , 2001, Molecular cell.
[31] K. Kihara,et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] Jeremy J. W. Chen,et al. Transcription Repressor Slug Promotes Carcinoma Invasion and Predicts Outcome of Patients with Lung Adenocarcinoma , 2005, Clinical Cancer Research.
[33] I. Wistuba,et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs , 2010, Nature.
[34] Yi Zheng,et al. p19Arf-p53 Tumor Suppressor Pathway Regulates Cell Motility by Suppression of Phosphoinositide 3-Kinase and Rac1 GTPase Activities* , 2003, The Journal of Biological Chemistry.
[35] P. Chumakov,et al. Tumor suppressor p53 and its homologue p73alpha affect cell migration. , 2003, The Journal of biological chemistry.
[36] E. Manser,et al. The RhoA GEF Syx Is a Target of Rnd3 and Regulated via a Raf1-Like Ubiquitin-Related Domain , 2010, PloS one.
[37] N. Voirin,et al. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype , 2009, British Journal of Cancer.
[38] R. Eves,et al. p53 Suppresses Src-Induced Podosome and Rosette Formation and Cellular Invasiveness through the Upregulation of Caldesmon , 2009, Molecular and Cellular Biology.
[39] S. Chi,et al. Frequent alteration of p63 expression in human primary bladder carcinomas. , 2000, Cancer research.
[40] J. Settleman,et al. Rnd Proteins Function as RhoA Antagonists by Activating p190 RhoGAP , 2003, Current Biology.
[41] Sarah A. Boswell,et al. RETRACTED: RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress , 2006, Current Biology.
[42] S. Lowe,et al. TAp63 induces senescence and suppresses tumorigenesis in vivo , 2009, Nature Cell Biology.
[43] C. Prives,et al. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? , 2007, Oncogene.
[44] V. Rotter,et al. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy , 2008, Cell cycle.
[45] D. Peeper,et al. Deregulating EMT and senescence: double impact by a single twist. , 2008, Cancer cell.
[46] J. Norman,et al. Integrins: masters and slaves of endocytic transport , 2009, Nature Reviews Molecular Cell Biology.
[47] S. Jakowlew. Transforming growth factor-beta in cancer and metastasis. , 2006, Cancer metastasis reviews.
[48] P. Coates,et al. p63 contributes to cell invasion and migration in squamous cell carcinoma of the head and neck. , 2008, Cancer letters.
[49] C. Prives,et al. A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain , 2001, Molecular and Cellular Biology.
[50] J. Garlick,et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. , 2007, Genes & development.
[51] W. Deppert,et al. Mutant p53R270H gain of function phenotype in a mouse model for oncogene‐induced mammary carcinogenesis , 2007, International journal of cancer.
[52] A. Lenferink,et al. Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.
[53] You-ji Feng,et al. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway , 2009, Molecular Cancer.
[54] G. Condorelli,et al. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro , 2010, The Journal of cell biology.
[55] V. Rotter,et al. Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor β1 (TGF-β1) Signaling Pathway by Repressing the Expression of TGF-β Receptor Type II , 2007, Molecular and Cellular Biology.
[56] B. Li,et al. neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice , 1997, Molecular and cellular biology.
[57] M. Mayo,et al. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. , 2008, Cancer research.
[58] Pierre Roux,et al. Control of cell migration: a tumour suppressor function for p53? , 2006, Biology of the cell.
[59] D. Notterman,et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.
[60] Yi Zheng,et al. Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion , 2004, Oncogene.
[61] J. Vandesompele,et al. Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo , 2010, Cell Death and Differentiation.
[62] Paul Timpson,et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.
[63] V. Rotter,et al. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53 , 2006, Oncogene.
[64] Pierre Roux,et al. Loss of p53 promotes RhoA–ROCK-dependent cell migration and invasion in 3D matrices , 2007, The Journal of cell biology.
[65] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[66] Bei Wang,et al. LIM and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. , 2009, Journal of hepatology.
[67] V. Rotter,et al. Mutant p53R175H upregulates Twist1 expression and promotes epithelial–mesenchymal transition in immortalized prostate cells , 2011, Cell Death and Differentiation.
[68] A. Levine,et al. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. , 1995, Oncogene.
[69] P. Roux,et al. Regulation of Cdc42‐mediated morphological effects: a novel function for p53 , 2002, The EMBO journal.
[70] F. Ferrari,et al. A MicroRNA Targeting Dicer for Metastasis Control , 2010, Cell.
[71] Y. Soini,et al. A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. , 2003, European journal of cancer.
[72] J. Norman,et al. Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.
[73] Jesse D. Martinez,et al. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. , 2008, Neoplasia.
[74] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[75] C. Cordon-Cardo,et al. Loss of p63 expression is associated with tumor progression in bladder cancer. , 2002, The American journal of pathology.
[76] V. Rotter,et al. Integrity of the N‐terminal transcription domain of p53 is required for mutant p53 interference with drug‐induced apoptosis , 2001, The EMBO journal.
[77] V. Rotter,et al. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. , 2007, Molecular and cellular biology.
[78] B. Kennedy,et al. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.
[79] P. Chumakov,et al. Tumor Suppressor p53 and Its Homologue p73α Affect Cell Migration* , 2003, Journal of Biological Chemistry.
[80] M. Baudry,et al. A Novel Function for p53: Regulation of Growth Cone Motility through Interaction with Rho Kinase , 2009, The Journal of Neuroscience.
[81] I. Simon,et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. , 2010, Cancer cell.
[82] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[83] Andrew J. Lindsay,et al. Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments , 2008, The Journal of cell biology.
[84] A. Yang,et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. , 2005, Cancer cell.
[85] Margaret Ashcroft,et al. Regulation of p53 stability , 1999, Oncogene.
[86] Hyojin Cho,et al. Many new down‐ and up‐regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers , 2010, Journal of cellular physiology.
[87] Misako Sato,et al. P63 expression in normal, hyperplastic and malignant breast tissues , 2002, Breast cancer.
[88] V. Rotter,et al. Mutant p53 protein expression interferes with p53-independent apoptotic pathways , 1998, Oncogene.
[89] Erik Sahai,et al. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis , 2003, Nature Cell Biology.
[90] C. Kang,et al. Downregulation of Dicer enhances tumor cell proliferation and invasion. , 2010, International journal of oncology.
[91] V. Rotter,et al. Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function , 2004, Cancer Research.
[92] A. Hall,et al. Rho GTPases and their effector proteins. , 2000, The Biochemical journal.
[93] M. Kapoor,et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[94] M. Sarbia,et al. Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down‐regulation of E‐cadherin , 2007, The Journal of pathology.
[95] T. Fleming,et al. Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. , 2009, Cancer research.
[96] Jos Jonkers,et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. , 2006, Cancer cell.
[97] A. Balmain,et al. Expression pattern of the cell adhesion molecules. E-cadherin, P-cadherin and alpha 6 beta 4 intergrin is altered in pre-malignant skin tumors of p53-deficient mice. , 1996, International journal of cancer.
[98] Antonio Rosato,et al. A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.
[99] A. Balmain,et al. Expression pattern of the cell adhesion molecules E‐cadherin, P‐cadherin and α6β4 integrin is altered in pre‐malignant skin tumors of p53‐deficient mice , 1996 .
[100] S. Nomoto,et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. , 2003, Cancer research.
[101] M. Hollstein,et al. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.
[102] Y. Xu,et al. A common gain of function of p53 cancer mutants in inducing genetic instability , 2010, Oncogene.
[103] Jason S. Carroll,et al. p63 regulates an adhesion programme and cell survival in epithelial cells , 2006, Nature Cell Biology.
[104] V. Rotter,et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells , 2010, The Journal of experimental medicine.
[105] J. Vasiliev,et al. Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization , 2000, Oncogene.
[106] A. Levine,et al. Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73* , 2000, The Journal of Biological Chemistry.